Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial
- 19 May 2008
- journal article
- research article
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 39 (2) , 267-276
- https://doi.org/10.1017/s0033291708003401
Abstract
Background This study examined the efficacy and tolerability of duloxetine and venlafaxine extended-release (XR) treatment for generalized anxiety disorder (GAD), with a secondary focus on psychic and somatic symptoms within GAD.Keywords
This publication has 22 references indexed in Scilit:
- Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trialInternational Clinical Psychopharmacology, 2007
- Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trialsCurrent Medical Research and Opinion, 2007
- Efficacy of Duloxetine for the Treatment of Generalized Anxiety DisorderThe Primary Care Companion For CNS Disorders, 2007
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- GratitudeThe Journal of Clinical Psychiatry, 2002
- Efficacy of Extended-Release Venlafaxine in Nondepressed Outpatients With Generalized Anxiety DisorderAmerican Journal of Psychiatry, 2000
- An overview of generalized anxiety disorder: disease state—appropriate therapyClinical Therapeutics, 2000
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- Symptomatic volunteers in multicenter drug trialsProgress in Neuro-Psychopharmacology, 1979
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959